RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

• প্রধান লেখক: Hai-Zhou Wu (লেখক), Lan-Ya Li (লেখক), Shi-Long Jiang (লেখক), Yi-Zhi Li (লেখক), Xiao-Mei Shi (লেখক), Xin-Yuan Sun (লেখক), Zhuo Li (লেখক), Yan Cheng (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAFV600E mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAFV600E mutant melanoma. Here we found that RSK2 is overexpressed in melan...